"); //-->
|
|
||
Strattera |
|||
|
|
|||
|
|||
|
|
|||
|   | |||
|
|
|||
|
|
Questions to be answered references as our understanding of the mechanisms by which estrogens affect the cardiovascular system has increased, it has become clear that the complexity of the biological effects of estrogens are reflective of quite complex mechanisms of action 7, 8.
ADHD treated with Aripiprazole Abilify ; . Investigator: Robert L. Findling, M.D. Sponsor: Investigator-Initiated. Contact: Corrie Nesselhauf, 216-844-3922. Adult ADHD treated with Atomoxetine Stratterra ; . Investigator: Robert L. Findling, M.D. Sponsor: Eli Lilly. Contact: Corrie Nesselhauf, 216-844-3922. At-Risk Children with symtoms of Bipolar Disorder treated with Aripiprazole Abilify ; or placebo. Investigator: Robert L. Findling, M.D. Sponsor: Stanley Medical Research Institute. Contact: Corrie Nesselhauf, 216-844-3922. Bipolar I Disorder treated with Quetiepine. Strattera no prescriptionMissed dose if patients miss a dose, they should be instructed to take it as soon as possible, but should not take more than the prescribed total daily amount of strattera in any 24-hour period and trileptal. Analysis Appellant's own testimony indicates prior authorization was not requested prior to purchasing the 07 31 04 prescription. In accordance with the Ohio Admin. Code, prior authorization must be obtained before the drug may be dispensed if it is not listed in Appendix A of Ohio Admin. Code 5101: 3-9-12. The Hearing Officer reviewed Appendix A and finds the drug Stratteera is listed as a covered drug. There is no indication in Appendix A that prior authorization is required. However, the Hearing Officer reviewed the Ohio Medicaid Drug List which reflects that Strrattera is approved for children six years old and older. The Hearing Officer finds prior authorization was required because the minor child was under the age of six years old. Prior authorization was not requested or authorized prior to the 07 31 04 purchase of the drug. Furthermore, the hearing request is untimely. The denial was issued 08 06 04 and received by Appellant. The state hearing request was not received in the Bureau of State Hearings until 11 08 04, which exceeds the ninety day limit for requesting a state hearing. The time period for requesting a state hearing expired. Term, although in the medium term an increasing number of adult psychiatrists and adult mental health services are expected to incorporate treatment of ADHD into their general practice. The short-term effectiveness of stimulants in adult life has been demonstrated with meta-analysis of available data showing similar effect sizes to that seen in child and adolescent samples [17]. They concluded that the degree of efficacy of MPH, in treating adults with ADHD, was similar to that reported from metaanalyses of the child and adolescent literature, providing assurance for clinicians that the diagnosis and treatment of ADHD can be validly applied in adulthood. The one area where different parameters may operate is dosage level. Titration to an effective dose is important [17]. The most common dose range used in European adult ADHD clinics for IR methylphenidate is 1020 mg taken 35 times daily, with both higher and lower dosing required in individual cases. Our suggested maximum is 30 mg for each dose. The use of extended release stimulants has been less extensively investigated in the adult ADHD population but the similarity in treatment effect sizes for IR MPH suggests that the guidelines for their use in older children and adolescents should be followed for adults. As with IR preparations titration to a clinically effective dose is required. One large trial of Concerta XL [6] involved a randomised, 6-week, placebo-controlled, parallel design study of Concerta XL in 103 adult patients with DSM-IV ADHD. Dosage could be titrated up to 1.3 mg kg day; the average daily dose used in this study was 72 mg, and the maximum 108 mg day. For an adult with a long working day and responsibilities in the evening, or where marked behavioural symptoms such as irritability and impulsivity appear once the effects of medication wear off alternative treatment may be needed. Careful consideration of the timing of reappearance of symptoms and the PK profile of each drug should be considered in deciding whether to opt for a supplement of IR medication or a change to Stratrera see below ; . Similar treatment effect sizes to those seen in children have also been shown within available drug trials of Sstrattera [1, 44, 56]. As in children the possible advantages include reduced potential for drug misuse, extended action throughout the day and a different profile of side effects and hazards. The usual daily dose for adults is 100 mg taken once per day. The same arguments for and against the use of extended release preparations in children and adolescents also apply to adults. The main difference here is the way that the treatment options are evaluated since adult patients are often capable of providing detailed descriptions of their personal preferences. The main indications for choosing ER preparations include compliance and antabuse. ROBINUL . ROBINUL FORTE ROCALTROL . ROCEPHIN . ROFERON-A RONDEC . ROSAC . ROSULA . ROSULA NS ROWASA . ROXANOL . ROXICET . ROXICODONE . ROZEREM . ROZEX . RUM-K RYNA-12 RYNA-12 S . RYNATAN RYTHMOL . RYTHMOL SR SILVADENE . SILVER NITRATE . silver sulfadiazine . SIMETYL . SIMULECT simvastatin SINA-12X SINEMET . SINEMET CR SINGULAIR . SINUVENT PE SITREX . SKELAXIN . SKELID sodium chloride irrigation soln . 2 sodium citrate citric acid soln . 42 SODIUM FLUORIDE . 24, 42 sodium fluoride . 24, 42 sodium polystyrene sulfonate 11 sodium thiosulfate salicylic acid . SOLARAZE . SOMA . SOMA COMPOUND . SOMA CPD WITH CODEINE . 41 SOMAVERT . SOMNOTE . SONATA . SORIATANE . sotalol . sotalol AF SPECTAZOLE . SPECTRACEF . SPIRIVA HANDIHALER . spironolactone . spironolactone hydrochlorothiazide . SPORANOX . SPRYCEL . STAFLEX . STAGESIC-10 STALEVO . stannous fluoride . STARLIX . STERAPRED . STIMATE . STRATTERA . STREPTOMYCIN STRIANT . STROMECTOL . SUBOXONE. Strattera ingredientsACCU-CHEK MONITORS, STRIPS ACTONEL, ACTONEL W CALCIUM ACTOPLUS MET ACTOS ACULAR ADDERALL XR ADVAIR ADVICOR AGENERASE AGRYLIN ALDARA ALINIA ALKERAN ALOCRIL ALOMIDE ALPHAGAN P ALTACE AMBIEN QL 30 ; ANDRODERM ANZEMET QL 5 ; APIDRA APTIVUS ARICEPT ARIMIDEX ASACOL ASMANEX ASTELIN NASAL SPRAY ATROVENT INHALER AVANDIA AVANDAMET AVANDARYL AVODART AZMACORT AZOPT BACTROBAN CREAM BARACLUDE BENICAR, BENICAR HCT BYETTA QL ; CANASA CASODEX CEENU CELLCEPT CELONTIN CENESTIN CHEMSTRIPS CILOXAN CIPRODEX CLINDAGEL QL 40ml ; CLOBEX COLY-MYCIN S COMBIPATCH COMBIVENT COMBIVIR COMTAN CONCERTA QL ; CONDYLOX GEL COREG CORTIFOAM CORTISPORIN TOPICAL COSOPT COZAAR QL 30 ; CRESTOR CRIXIVAN CYMBALTA CYTADREN CYTOMEL DAPSONE DARANIDE DEPAKOTE, DEPAKOTE ER DIAMOX SEQUELS DIASTIX REAGENT urine test strips DIFFERIN DIOVAN DIOVAN HCT DIPENTUM DOVONEX DRITHOCREME, DRITHOCREME HP DRITHO-SCALP EFFEXOR, EFFEXOR XR EFUDEX ELIDEL QL 1 mo ; EMCYT EMEND PA req ; EMTRIVA ENABLEX ERGAMISOL EPIPEN, EPIPEN JR EPIVIR ESTINYL ESTRACE VAGINAL CREAM ESTRATEST, ESTRATEST HS ESTRING ETHMOZINE ESTROSTEP FE EVISTA EXELDERM EXJADE PA req ; FAMVIR FARESTON FEMARA FEMHRT FLOMAX FLORINEF FLOVENT FLOXIN OTIC FLUOROPLEX FML-S FORADIL FORTOVASE FOSAMAX, FOSAMAX PLUS D FOSRENOL FUROXONE GLEEVEC PA req ; GLUCAGON EMERGENCY KIT GLUCOVANCE HEPSERA HEXALEN HIVID HUMALOG, HUMALOG MIX HUMIBID PED CAPS HUMULIN INSULINS HYZAAR QL 30 ; IMITREX QL 9 ; INVIRASE KADIAN QL 60 ; KALETRA KENALOG IN ORABASE KLORVESS K-PHOS MF, K-PHOS KYTRIL QL 10 ; LAMICTAL LAMISIL TABS LAMPRENE LANTUS LEUKERAN LEVAQUIN QL 14 ; LEVEMIR LEXAPRO LEXIVA LOPROX LOTREL LUMIGAN QL 2.5ml ; LYSODREN MARINOL MATULANE MAXAIR MAXALT, MAXALT mlT QL 9 ; MEPHYTON MEPRON METADATE CD METROGEL 1% MIACALCIN NASAL SPRAY MINTEZOL MIRAPEX MONOLET LANCETS MYCELEX TROUCHES MYCOBUTIN MYFORTIC MYLERAN NAMENDA Step therapy ; NARDIL NASONEX NATACYN NEVENAC NEXAVAR PA req ; NIASPAN NILANDRON NITROLINGUAL SPRAY NORVASC NORVIR NOVOLIN INSULINS NOVOLOG NUVARING OCUFLOX OMNICEF OPTIVAR OTOBIOTIC OXYTROL PARNATE PAXIL CR PHOSLO PILOPINE HS PLAVIX POLY-PRED PRECOSE PRED MILD PRED-G PREMARIN TABS PREMPHASE PREMPRO PREVACID QL 30 ; PROGRAF PROTONIX QL 30 ; PROTOPIC OINTMENT QL 1 ; PULMICORT INHALER PULMICORT SOL PA 8yo ; PULMOZYME PA req ; PURINETHOL RAPAMUNE REBETOL PA req ; REQUIP RESCRIPTOR RETIN-A MICRO PA 30yo ; REVATIO PA req ; REVLIMID PA req ; REYATAZ RIDAURA RILUTEK RISPERDAL SENSIPAR SEREVENT SEROQUEL SINGULAIR SOFT TOUCH lancets and device SOFTCLIX lancets and device SPIRIVA STALEVO STARLIX STRATTERA SULAR SUPRAX SUSTIVA SYMLIN QL ; SYNTHROID TAZORAC PA 30yo ; TEGRETOL XR TESLAC TESTIM QL ; THYROLAR TILADE TOBI SOL TOBRADEX TONOCARD TOPAMAX TOPROL XL QL 1 day ; TORECAN TABS TRACLEER PA req ; TRICOR TRIZIVIR TRUSOPT TRUVADA UROXATRAL VAGIFEM VALCYTE VALTREX VANCERIL INH VELOSULIN VENTAVIS VENTOLIN ROTACAPS VESICARE VIDEX VIRA-A VIRACEPT VIRAMUNE VIREAD VYTORIN VOLTAREN EYE DROPS XIBROM ZANTAC syrup Age 16yo ; ZEMPLAR ZERIT ZETIA ZIAGEN ZOFRAN 4MG, 8mg QL 12 ; ZOVIRAX OINTMENT ZYMAR QL 2.5ml ; ZYPREXA and pletal. Strattera for womenBiotechnology company, and, from 1995 to 1997, he was also chief financial officer of Affymetrix. Prior to joining Affymetrix, Mr. Nussbacher was executive vice president for business and legal affairs of Affymax Research Institute. He received a B.S. from Cooper Union and a J.D. from Duke University. Mr. Nussbacher is also a member of the board of directors of Symyx Technologies, Inc., a publicly-traded company specializing in high-throughput experimentation for the discovery of materials. Bryan E. Roberts has been a member of our board of directors since 2000. He joined Venrock Associates, a venture capital investment firm, in 1997 and has been a general partner there since 2001. From 1989 to 1992, Dr. Roberts worked in the Corporate Finance Department of Kidder, Peabody & Co., a brokerage company. He received a B.A. from Dartmouth University and a Ph.D. in chemistry and chemical biology from Harvard University. Dr. Roberts is also a member of the board of directors of the publicly-traded company Sirna Therapeutics, Inc., a company that develops therapeutics based on RNA interference technology. Gary D. Tollefson has been a member of our board of directors since September 2005. He has been chief executive officer of Orexigen Therapeutics, a private biotechnology company that is developing novel therapeutics for the treatment of obesity, since April 2005. From June 1991 to April 2004, Dr. Tollefson was at Eli Lilly and Company, where he served in a number of senior leadership roles. As president of the Neuroscience Product Group, he developed global neuroscience product strategies encompassing both commercial and clinical product development. During his career with Lilly, he led the efforts resulting in the launch and or product lifecycle implementation for several important neuroscience products, including the antidepressant Prozac, Strattera for attentiondeficit ADHD ; , Symbyax for bipolar depression, Cymbalta for major depression neuropathic pain and the psychotropic Zyprexa including a series of line extensions ; . Dr. Tollefson, an expert in the area of psychopharmacology, is also president of Consilium, Inc., a consulting firm focused on the development of CNS products. He is a Volunteer Clinical Professor in the Department of Psychiatry, Indiana University School of Medicine and currently holds a senior guest scientific position with Eli Lilly and Company as the Distinguished Visiting Lilly Research Scholar. Dr. Tollefson received a B.A., M.D. and Ph.D. in psychiatry from the University of Minnesota. Dr. Tollefson is also a member of the board of directors of two publicly-traded pharmaceutical companies, Cortex Pharmaceuticals, Inc. and Cypress Bioscience, Inc. Wendell Wierenga has been a member of our board of directors since 2001. He has been executive vice president of research and development at Neurocrine Biosciences, Inc., a biopharmaceutical company developing therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases, since September 2003. From 2000 to 2003, Dr. Wierenga was chief executive officer of Syrrx, Inc., a company focused on small-molecule drug compounds. Prior to joining Syrrx, from 1990 to 2000, he was senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis, a division of Warner Lambert Co., a pharmaceutical company. Pfizer Inc, a research-based pharmaceutical company, acquired Warner Lambert in 2000. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co., later Pharmacia & Upjohn, Inc., a pharmaceutical and biotechnology company, for 16 years in various positions, most recently as executive director of discovery research. Pfizer acquired Pharmacia & Upjohn, then named Pharmacia Corp., in 2002. Dr. Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University. Dr. Wierenga is a member of the boards of directors of the publicly-traded companies Ciphergen Biosystems, Inc., a protein technology products and services company, and Onyx Pharmaceuticals, Inc., a biopharmaceutical company. Election of Officers Our officers are elected by our board of directors and serve until their successors are duly elected and qualified. There are no family relationships among any of our officers or directors. Board of Directors Our board of directors currently consists of eight members. Drs. Freund, Barrett and Wierenga and Mr. Nussbacher were elected in accordance with the terms of a voting agreement that terminated upon the closing of our initial public offering in 2005. Ms. Hilleman and Mr. Berns were each elected by our board of directors to fill a vacancy in accordance with our amended and restated certificate of incorporation and bylaws. Drs. Roberts and Tollefson were re-elected by our stockholders at our 2006 annual meeting of stockholders. 70 and cyklokapron. COMPOSITION: atomoxetine hydrochloride. PRESENTATION: hard capsules. ACTION: selective inhibitor of the pre-synaptic noradrenaline transporter. INDICATIONS: treatment of attention-deficit hyperactivity disorder ADHD ; in children six years of age and older, adolescents and adults. DOSAGE: children and adolescents up to 70kg body weight: initiation dose approximately 0.5mg kg per day, recommended maintenance dose approximately 1.2mg kg per day. Children and adolescents over 70kg body weight and adults: initiation dose 40mg per day, recommended maintenance dose 80mg per day. CAUTIONS: atomoxetine should be used with caution in patients with hypertension, tachycardia or cardiovascular or cerebrovascular disease. Growth should be monitored during treatment. Atomoxetine may exacerbate hypertension in patients with end stage renal failure. Doses should be reduced in those with moderate hepatic insufficiency. See SPC. CONTRAINDICATIONS: atomoxetine should not be used in combination with monoamine oxidase inhibitors. Not recommended in patients with narrow angle glaucoma. SIDE EFFECTS: abdominal pain, decreased appetite. NET PRICE: 7 10mg, 18mg, or 40mg ; 13.65 , 28 10mg, 18mg, or 60mg ; 54.60. CONTACT DETAILS: Eli Lilly & Co, Lilly House, Priestly Road, Basingstoke, Hampshire RG24 9NL tel 01256 315999 ; . Strattera will be available to order from 7 July.
It has been suggested that only about 30% of women experience progressive disease while other either remain in a steady state or deteriorate Farquhar, 2004 ; . Recurrence is common once hormonal treatment is discontinued. In trials of treatment with GnRH analogues or danazol, about 10-20% of women required further treatment within 12 months. Uncontrolled cohort studies reported recurrence rates of about 50% at 5 years. Cohort studies of surgical treatment of endometriosis report 20% relapse at 5 years after surgery. But extended follow-up trials are required to determine the likelihood of recurrence in the long term Farquhar and Sutton, 1998. More than half of the people living with aids use health care services provided by state medicaid programs and buy indinavir. I attest that the information I have given is true and accurate to the best of my knowledge and that I the individual completing this form. I hereby authorize TMI to release this Respiratory Therapy Checklist to the Client facilities in relation to consideration of employment as a Traveler with those facilities. Cost of StratteraDone with Strattera for genotyping was done retrospectively. We did collect some things.
Prescription DrugsStratyera, strattea, stratter, strat5era, strattrea, strahtera, stratteera, stratttera, stra6tera, stratetra, stragtera, stratterz, strathera, strattfra, strattrra, stfattera, strsttera, strattra, strattefa, dtrattera, strxttera, stratteraa, stratt3ra, sstrattera, stratttera, srattera, strat6era, st5attera, stratteda, strattega, strwttera, stdattera, tsrattera, stratera, stratrera, st4attera, sttattera, steattera, stratte4a, s6rattera, syrattera. |
||
|
|
© 2007 | ||